The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS: We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis. RESULTS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival. Type 1 tumors were associated with MET alterations, whereas type 2 tumors were characterized by CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2-antioxidant response element (ARE) pathway. A CpG island methylator phenotype (CIMP) was observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the gene encoding fumarate hydratase (FH). CONCLUSIONS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renal-cell carcinoma consisted of at least three subtypes based on molecular and phenotypic features. (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“another possible mechanism by which D-2-HG drives tumorigenesis is through the promotion of genetic instability, predisposing cells to oncogenic transformation103.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
In the citing paper
“Genomic studies have established that somatic mutations in IDH1 and IDH2 are perhaps the first genetic events to occur during tumorigenesis in human glioma and AML, and appear to initiate pathogenesis by a common mechanism103,115-117.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
In the citing paper
“The most commonly occurring cancers thought to arise from mutant IDH1/2 (mIDH1/2) include glioma, cartilaginous tumours, AML, angioimmunoblastic T cell lymphoma (AITL) and intrahepatic cholangiocarcinoma (ICC).”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Self-citationComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Self-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Flagged first, then by citations
1 of the 42 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Delahunt B, 1997, Mod Pathol, 10, 537
- Schmidt LS, 1998, Cancer Res, 58, 1719
Cited by
Sorted by citations
Items 401–500 of 1,000
The role of TFEB in tumor cell autophagy: Diagnostic and therapeutic opportunities
Bahrami, A., Bianconi, V., Pirro, M., Orafai, H. M., & Sahebkar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117341 · Cited by 29
Ji, Z., Huo, C., & Yang, P. (2020) · International Urology and Nephrology · doi:10.1007/s11255-019-02372-2 · Cited by 30
Li, J., Huang, K., Thakur, M., McBride, F., Sadagopan, A., Gallant, D. S., Khanna, P., Laimon, Y. N., Li, B., Mohanna, R. A., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01218-9 · Cited by 29
Paulucci, D. J., Sfakianos, J. P., Skanderup, A. J., Kan, K. M., Tsao, C., Galsky, M. D., Hakimi, A. A., & Badani, K. K. (2016) · Oncotarget · doi:10.18632/oncotarget.14122 · Cited by 29
Bodokh, Y., Ambrosetti, D., Kubiniek, V., Tibi, B., Durand, M., Amiel, J., Pertuit, M., Barlier, A., & Pédeutour, F. (2017) · Cancer Genetics · doi:10.1016/j.cancergen.2017.11.010 · Cited by 28
Ishihara, H., Yamashita, S., Liu, Y., Hattori, N., El‐Omar, O., Ikeda, T., Fukuda, H., Yoshida, K., Takagi, T., Taneda, S., et al. (2020) · Cancer Science · doi:10.1111/cas.14633 · Cited by 29
Wu, J., Liu, T., Sun, L., Zhang, S., & Dong, G. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01606-z · Cited by 28
Tjota, M. Y., Wanjari, P., Segal, J. P., & Antic, T. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.12.006 · Cited by 28
Checkpoint inhibitors in metastatic papillary renal cell carcinoma
Vries-Brilland, M. D., McDermott, D. F., Suárez, C., Powles, T. B., Gross‐Goupil, M., Ravaud, A., Flippot, R., Escudier, B. J., & Albiges, L. K. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102228 · Cited by 28
CpG Island Methylator Phenotype—A Hope for the Future or a Road to Nowhere?
Karpiński, P., & Sasiadek, M. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020830 · Cited by 30
Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma
Sharma, R., Kannourakis, G., Prithviraj, P., & Ahmed, N. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.766869 · Cited by 30
Tumorigenesis Mechanisms Found in Hereditary Renal Cell Carcinoma: A Review
Webster, B. R., Gopal, N., & Ball, M. W. (2022) · Genes · doi:10.3390/genes13112122 · Cited by 28
Liang, J., Sun, G., Pan, X., Zhang, M., Shen, P., Zhu, S., Zhao, J., Zheng, L., Zhao, J., Chen, Y., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01182-7 · Cited by 28
Saleeb, R., Plant, P. J., Tawedrous, E., Krizova, A., Brimo, F., Evans, A. J., Wala, S. J., Bartlett, J. M. S., Ding, Q., Boles, D., et al. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.09.002 · Cited by 28
Using association signal annotations to boost similarity network fusion
Ruan, P., Wang, Y., Shen, R., & Wang, S. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz124 · Cited by 28
Ahmad, A., Paffrath, V., Clima, R., Busch, J. F., Rabien, A., Kilic, E., Villegas, S. L., Timmermann, B., Attimonelli, M., Jung, K., et al. (2019) · Cancers · doi:10.3390/cancers11091298 · Cited by 28
Testa, U., Pelosi, E., & Castelli, G. (2020) · Medicines · doi:10.3390/medicines7080044 · Cited by 30
Nguyen, T. N. A., Lai, H.-T., Fernandes, R., Dall’Olio, F. G., Blériot, C., Ha‐Duong, T., & Brenner, C. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02272-2 · Cited by 27
Brooks, S. A., Khandani, A. H., Fielding, J. R., Lin, W., Sills, T., Lee, Y. Z., Arreola, A., Milowsky, M. I., Wallen, E., Woods, M. E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2115 · Cited by 27
Négrier, S., Moriceau, G., Attignon, V., Haddad, V., Pissaloux, D., Guerin, N., & Carrié, C. (2018) · Journal of Medical Case Reports · doi:10.1186/s13256-018-1875-9 · Cited by 27
Park, I., Shim, Y. S., Go, H., Hong, B. S., & Lee, J. (2019) · BMC Urology · doi:10.1186/s12894-019-0484-2 · Cited by 27
Colli, L. M., Jessop, L., Myers, T. A., Camp, S. Y., Machiela, M. J., Choi, J., Cunha, R., Onabajo, O. O., Mills, G. C., Schmid, V., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.07.009 · Cited by 27
Waehle, V., Ungricht, R., Hoppe, P. S., & Betschinger, J. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.07.023 · Cited by 29
Dubovenko, A., Nikolsky, Y., Rakhmatulin, E. A., & Nikolskaya, T. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7027-8_6 · Cited by 27
Kammerer‐Jacquet, S., Gandon, C., Dugay, F., Laguerre, B., Peyronnet, B., Mathiéu, R., Verhoest, G., Bensalah, K., Leroy, X., Aubert, S., et al. (2022) · Histopathology · doi:10.1111/his.14683 · Cited by 27
Chen, M., Nie, J., Liu, Y., Li, X., Zhang, Y., Brock, M. V., Feng, K., Wu, Z., Li, X., Shi, L., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31531 · Cited by 27
Greene, C., Sharma, N. J., Fiorica, P. N., Forrester, E. J., Smith, G. J., Gross, K. W., & KAUFFMAN, E. C. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.12.013 · Cited by 28
KAUFFMAN, E. C., Lang, M., Rais‐Bahrami, S., Gupta, G. N., Wei, D., Yang, Y., Sourbier, C., & Srinivasan, R. (2019) · BMC Cancer · doi:10.1186/s12885-019-6096-0 · Cited by 27
SEOM clinical guideline for treatment of kidney cancer (2019)
Lázaro-Quintela, M., Valderrama, B. P., Suárez, C., de Velasco, G., Beato, C., Chirivella, I., del Alba, A. G., Laínez, N., Méndez-Vidal, M. J., & Arranz, J. Á. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02285-7 · Cited by 28
Armstrong, A. J., Nixon, A. B., Carmack, A., Yang, Q., Eisen, T. G., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4504 · Cited by 27
Wang, T., Qin, Y., Zeng, Y., Jing, D., Fan, G., Liu, M., Zhuo, Q., Ji, S., Chen, X., Yu, X., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01078-7 · Cited by 27
Modi, P. K., Farber, N. J., & Singer, E. A. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.06.05 · Cited by 26
Bayesian variable selection for survival data using inverse moment priors
Nikooie, A., Wang, W., & Johnson, V. E. (2020) · The Annals of Applied Statistics · doi:10.1214/20-aoas1325 · Cited by 26
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
Attalla, K., DiNatale, R. G., Rappold, P. M., Fong, C. J., Sánchez-Vega, F., Silagy, A. W., Weng, S., Coleman, J., Lee, C., Carlo, M. I., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4058 · Cited by 27
Pecci, F., Nakazawa, S., Ricciuti, B., Harada, G., Lee, J., Alessi, J. V., Barrichello, A. P. D. C., Vaz, V. R., Lamberti, G., Federico, A. D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1217 · Cited by 26
Molecular Signatures for Tumor Classification
Mamatjan, Y., Agnihotri, S., Goldenberg, A., Tonge, P. J., Mansouri, S., Zadeh, G. M., & Aldape, K. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.07.008 · Cited by 26
Niffenegger, J. H., Soltero, A., Niffenegger, J., Yang, S., & Adamus, G. (2018) · Journal of Clinical & Experimental Ophthalmology · doi:10.4172/2155-9570.1000740 · Cited by 26
Lameirinhas, A., Miranda‐Gonçalves, V., Henrique, R., & Jerónimo, C. (2019) · Genes · doi:10.3390/genes10040264 · Cited by 28
Hang, J., Chung, H., & Pan, C. (2020) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-020-02752-5 · Cited by 26
Biomarkers in renal cell carcinoma: Are we there yet?
Gulati, S., & Vogelzang, N. J. (2021) · Asian journal of urology · doi:10.1016/j.ajur.2021.05.013 · Cited by 26
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles
Barata, P. C., Gulati, S., Elliott, A., Hammers, H. J., Burgess, E. F., Gartrell, B. A., Darabi, S., Bilen, M. A., Basu, A., Geynisman, D. M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178915 · Cited by 26
Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer
Ravi, P. K., Bakouny, Z., Schmidt, A. L., & Choueiri, T. K. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000477 · Cited by 25
Sánchez‐Heras, A. B., Castillejo, A., García-Díaz, J. D. D., Robledo, M., Teulé, À., Sánchez‐Martínez, R., Zúñiga, Á., Lastra, E., Durán, M., Llort, G., et al. (2020) · Cancers · doi:10.3390/cancers12113277 · Cited by 25
Xiao, Y., Rabien, A., Buschow, R., Amtislavskiy, V., Busch, J. F., Kilic, E., Villegas, S. L., Timmermann, B., Schütte, M., Mielke, T., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1998 · Cited by 25
Zamora-Fuentes, J. M., Lemus, E. H., & Enríquez, J. E. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.578679 · Cited by 25
Finet, O., Yague‐Sanz, C., Marchand, F., & Hermand, D. (2022) · RNA Biology · doi:10.1080/15476286.2022.2078094 · Cited by 25
Novacescu, D., Feciche, B. O., Cumpănaş, A. A., Bardan, R. T., Rusmir, A. V., Bitar, Y. A., Barbos, V., Cut, T. G., Raica, M., & Latcu, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10112926 · Cited by 25
The Role of CT Imaging in Characterization of Small Renal Masses
Bazzocchi, M. V., Zilioli, C., Gallone, V. I., Commisso, C., Bertolotti, L., Pagnini, F., Ziglioli, F., Maestroni, U. V., Aliprandi, A., Buti, S., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13030334 · Cited by 25
Cimadamore, A., Gasparrini, S., Santoni, M., Liang Cheng, C., Antonio Lopez-beltran, B., Battelli, N., Massari, F., Giunchi, F., Fiorentino, M., Scarpelli, M., et al. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1490179 · Cited by 25
Panda, A., Yadav, A., Yeerna, H., Singh, A., Biehl, M. L., Lux, M., Schulz, A., Klecha, T., Doniach, S., Khiabanian, H., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa485 · Cited by 25
Denize, T., Just, P. A., Sibony, M., Blons, H., Timsit, M., Drossart, T., Jakubowicz, D., Broudin, C., Morini, A., Molina, T. J., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0645-6 · Cited by 25
Trans-ethnic variation in germline variants of patients with renal cell carcinoma
Alaiwi, S. A., Nassar, A. H., Adib, E., Groha, S., Akl, E. W., McGregor, B. A., Esplin, E. D., Yang, S., Hatchell, K. E., Fusaro, V. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108926 · Cited by 26
N6-methyladenosine (m6A) methylation in kidney diseases: Mechanisms and therapeutic potential
Sun, Y., Jin, D., Zhang, Z., Ji, H., An, X., Zhang, Y., Yang, C., Sun, W., Zhang, Y., Duan, Y., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2023.194967 · Cited by 26
Haake, S. M., Li, J., Bai, Y., Kinose, F., Fang, B., Welsh, E. A., Zent, R., Dhillon, J., Pow‐Sang, J. M., Chen, Y. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1673 · Cited by 24
Predictive values of Notch signalling in renal carcinoma
Jędroszka, D., Orzechowska, M., & Bednarek, A. K. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.65649 · Cited by 24
Zhao, Q., Jia, X., Hong, B., Qian, W., Liu, T., Fan, B., Cai, J., Ji, Y., Liu, J., Yang, Y., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01552-w · Cited by 24
Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis
Wang, Y., Yan, K., Lin, J., Wang, J., Zheng, Z., Li, X., Hua, Z., Bu, Y., Shi, J., Sun, S., et al. (2020) · Aging · doi:10.18632/aging.104001 · Cited by 24
Wu, J., Dong, G., Liu, T., Zhang, S., Sun, L., & Liang, W. (2021) · Aging · doi:10.18632/aging.203440 · Cited by 24
Yates, J., & Boeva, V. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab610 · Cited by 24
Loeffler, C. M. L., Gaisa, N. T., Muti, H. S., van Treeck, M., Echle, A., Laleh, N. G., Trautwein, C., Heij, L. R., Grabsch, H. I., Bruechle, N. O., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.806386 · Cited by 25
Shen, M., Yin, X., Bai, Y., Zhang, H., Ru, G., He, X., Teng, X., Chen, G., & Zhao, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.930296 · Cited by 24
International cancer seminars: a focus on kidney cancer
Scélo, G., Hofmann, J. N., Banks, R. E., Bigot, P., Bhatt, R. S., Cancel‐Tassin, G., Chew, S. K., Creighton, C. J., Cussenot, O., Davis, I. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw186 · Cited by 24
Hereditary Renal Tumor Syndromes: Update on Diagnosis and Management
Gaur, S., Türkbey, B., & Choyke, P. L. (2016) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2016.10.002 · Cited by 24
Lee, C., Gundem, G., Lee, W., Chen, Y., Cross, J. R., Dong, Y., Redzematovic, A., Mano, R., Wei, E. Y., Cheng, E. H. Y., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00007 · Cited by 24
Hasumi, H., Furuya, M., Tatsuno, K., Yamamoto, S., Baba, M., Hasumi, Y., Isono, Y., Suzuki, K., Jikuya, R., Otake, S., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy181 · Cited by 24
Lan, B., & Xiaojing, L. (2018) · Academic Radiology · doi:10.1016/j.acra.2018.05.002 · Cited by 24
Yamaguchi, Y., Kamai, T., Higashi, S., Murakami, S., Arai, K., Shirataki, H., & Yoshida, K. (2019) · BMC Cancer · doi:10.1186/s12885-019-6347-0 · Cited by 25
Bochtler, T., Reiling, A., Endris, V., Hielscher, T., Volckmar, A., Neumann, O., Kirchner, M., Budczies, J., Heukamp, L. C., Leichsenring, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32882 · Cited by 24
User guide to MiT‐TFE isoforms and post‐translational modifications
Vu, H. N., Dilshat, R., Fock, V., & Steingrı́msson, E. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12922 · Cited by 25
Comprehensive characterization of alternative splicing in renal cell carcinoma
Zhang, Y., Wu, X., Li, J., Sun, K., Li, H., Yan, L., Duan, C., Liu, H., Chen, K., Ye, Z., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab084 · Cited by 24
Re: WHO Classification of Tumours, 5th Edition, Volume 8: Urinary and Male Genital Tumours
Tateo, V., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2023) · European Urology · doi:10.1016/j.eururo.2023.04.030 · Cited by 24
Deshpande, A. S., Lang, W., McDowell, T. L., Sivakumar, S., Zhang, J., Wang, J., Lucas, F. A. S., Fowler, J., Kadara, H. N., & Scheet, P. A. (2018) · BMC Bioinformatics · doi:10.1186/s12859-017-1991-3 · Cited by 23
Vries-Brilland, M. D., Gross‐Goupil, M., Seegers, V., Boughalem, E., Beuselinck, B., Thibault, C., Chevreau, C., Ladoire, S., Barthélémy, P., Négrier, S., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.019 · Cited by 23
Le, X., Wang, X., Zhao, H., Chen, R., & Ge, P. (2020) · BMC Urology · doi:10.1186/s12894-020-00716-0 · Cited by 23
Caliò, A., Marletta, S., Brunelli, M., & Martignoni, G. (2023) · Pathologica · doi:10.32074/1591-951x-814 · Cited by 23
Huang, K., Gui, C., Xu, Y.-Z., Li, X., Zhao, H., Cao, J., Chen, Y., Pan, Y.-H., Liao, B., Cao, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50369-y · Cited by 23
Molecular profiling of renal cell carcinoma
Manley, B. J., & Hakimi, A. A. (2016) · Current Opinion in Urology · doi:10.1097/mou.0000000000000307 · Cited by 23
Clinicopathologic Features of Translocation Renal Cell Carcinoma
Ellati, R. T., Abukhiran, I. M., Alqasem, K. S., Jasser, J., Khzouz, J., Bisharat, T., Al-Saidi, I., & Al‐Daghmin, A. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.05.013 · Cited by 23
Fiorentino, M., Gruppioni, E., Massari, F., Giunchi, F., Altimari, A., Ciccarese, C., Bimbatti, D., Scarpa, A., Iacovelli, R., Porta, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12551 · Cited by 23
Integrative epigenetic and genetic pan-cancer somatic alteration portraits
Salas, L. A., Johnson, K. C., Koestler, D. C., O'Sullivan, D. E., & Christensen, B. C. (2017) · Epigenetics · doi:10.1080/15592294.2017.1319043 · Cited by 24
Hasumi, H., & Yao, M. (2018) · Cancer Science · doi:10.1111/cas.13503 · Cited by 24
Källberg, D., Vidman, L., & Rydén, P. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.632620 · Cited by 23
Repurposing RNA sequencing for discovery of RNA modifications in clinical cohorts
Tan, K., Ding, L., Wu, C.-S., Tenen, D. G., & Yang, H. H. (2021) · Science Advances · doi:10.1126/sciadv.abd2605 · Cited by 23
A Pan-Cancer Analysis of Tumor-Infiltrating B Cell Repertoires
Yu, K., Ravoor, A., Malats, N., Pineda, S., & Sirota, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.790119 · Cited by 23
Setting Research Priorities for Kidney Cancer
Jones, J. M., Bhatt, J. R., Avery, J., Laupacis, A., Cowan, K., Basappa, N. S., Basiuk, J., Canil, C., Al-Asaaed, S., Heng, D. Y. C., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.04.011 · Cited by 23
Genomic basis for RNA alterations revealed by whole-genome analyses of 27 cancer typesPreprint
PCAWG Transcriptome Core Group, Calabrese, C., Davidson, N. R., Fonseca, N. A., He, Y., Kahles, A., Lehmann, K.-V., Liu, F., Shiraishi, Y., Soulette, C. M., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/183889 · Cited by 25
Progress in Endocrine Neoplasia
Wells, S. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0384 · Cited by 22
Bensalah, K., Albiges, L. K., Bernhard, J., Bigot, P., Bodin, T., Boissier, R., Corréas, J.-M., Gimel, P., Hetet, J. F., Long, J., et al. (2018) · The French Journal of Urology · doi:10.1016/j.purol.2018.09.009 · Cited by 22
Retractedvan de Pol, J. A. A., George, L., van den Brandt, P. A., Baldewijns, M. M. L. L., & Schouten, L. J. (2020) · International Journal of Cancer · doi:10.1002/ijc.33193 · Cited by 22
Chen, L., Hu, B., Song, X., Wang, L., Ju, M., Li, Z., Zhou, C., Zhang, M., Wei, Q., Guan, Q., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.598017 · Cited by 22
Choueiri, T. K., Albiges, L. K., Atkins, M. B., Bakouny, Z., Bratslavsky, G., Braun, D. A., Haas, N. B., Haanen, J. B. A. G., Hakimi, A. A., Jewett, M. A. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3238 · Cited by 22
Jikuya, R., Murakami, K., Nishiyama, A., Kato, I., Furuya, M., Nakabayashi, J., Ramilowski, J. A., Hamanoue, H., Maejima, K., Fujita, M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104463 · Cited by 23
Greene, C., Attwood, K. M., Sharma, N. J., Balderman, B., Deng, R., Muhitch, J. B., Smith, G. J., Gross, K. W., Xu, B., & KAUFFMAN, E. C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.923043 · Cited by 23
Delineating the interplay between oncogenic pathways and immunity in anaplastic Wilms tumors
Su, X., Lu, X., Bazai, S. K., Dainese, L., Verschuur, A. C., Dumont, B., Mouawad, R., Xu, L., Cheng, W., Yan, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43290-3 · Cited by 22
Renal cell cancer: overview of the current therapeutic landscape
Erman, M., Beneklı, M., Başaran, M., Bavbek, S. E., Buyukberber, S., Çoşkun, U., Demir, G., Karabulut, B., Öksüzoğlu, B. Ç., Özkan, M., et al. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1222908 · Cited by 22
Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma
Santos, M., Lanillos, J., Roldán‐Romero, J. M., Caleiras, E. J., Montero‐Conde, C., Cascón, A., Climent, M. Á., Anguera, G., Hernando, S., Laínez, N., et al. (2021) · Genetics in Medicine · doi:10.1038/s41436-020-01062-0 · Cited by 22
Toward a genome-based treatment landscape for renal cell carcinoma
Massari, F., Nunno, V. D., Santoni, M., Gatto, L., Caserta, C., Morelli, F., Zafarana, E., Carrozza, F., Mosca, A., Mollica, V., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.020 · Cited by 21
Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma
Gulati, S., Philip, E. J., Salgia, S. K., & Pal, S. K. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100172 · Cited by 23
The role of immunotherapy in non-clear cell renal cell carcinoma
Climent, C., Soriano, S., Bonfill, T., López, N. V., Rodríguez-Castells, M., Sierra, M., Cobo, P. A., Gil, M. F., Busquets, M., Carrasco, A., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.941835 · Cited by 21
Backman, S., Botling, J., Nord, H., Ghosal, S., Stalberg, P. L. H., Juhlin, C. C., Almlöf, J. C., Sundin, A., Zhang, L., Moens, L., et al. (2024) · The Journal of Pathology · doi:10.1002/path.6348 · Cited by 22
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- The Cancer Genome Atlas Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-01-14
- Volume
- 374
- Issue
- 2
- Pages
- 135-145
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4775252
- OpenAlex
- W2111867681
- Cited by
- 1,336
- References
- 42
- Citations by year
- 2026: 60 · 2025: 100 · 2024: 95 · 2023: 130 · 2022: 135 · 2021: 159 · 2020: 153 · 2019: 151 · 2018: 128 · 2017: 126 · 2016: 96
- FWCI
- 92.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (K24CA172355, U24CA143882, U24CA143843, U24CA143840, U24CA143858, U24CA144025, U24CA143866, U24CA199461, U24CA143883, U24CA143845, U24CA180951, U24CA143867, R01CA169172, U24CA143848, U24CA143799, U24CA143835, P30CA008748, P30CA015083, P30CA016672, P30CA016056, P30CA016086)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- papillary renal cell carcinoma, type 2 papillary renal cell carcinoma, MET alterations, SETD2 mutation, TFE3 fusion, Nrf2/ARE pathway, CpG island methylator phenotype, tumor subtypes, prognosis, molecular heterogeneity
- MeSH terms
- Carcinoma, Papillary, Humans, Kidney Neoplasms, Mutation, Phenotype, RNA, Messenger, RNA, Neoplasm, Signal Transduction, Sequence Analysis, RNA, CpG Islands, DNA Methylation, Proto-Oncogene Proteins c-met, MicroRNAs, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
